Please use this identifier to cite or link to this item:
http://hdl.handle.net/2440/107353
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial |
Author: | Chen, J. Hill, C. Lester, S. Ruediger, C. Battersby, R. Jones, G. Cleland, L. March, L. |
Citation: | Osteoporosis International, 2016; 27(5):1897-1905 |
Publisher: | Springer London |
Issue Date: | 2016 |
ISSN: | 0937-941X 1433-2965 |
Statement of Responsibility: | J. S. Chen, C. L. Hill, S. Lester, C. D. Ruediger, R. Battersby, G. Jones, L. G. Cleland, L. M. March |
Abstract: | This study aimed to determine the effect of fish oil on bone mineral density (BMD). There were no differences in the 2-year BMD measures between high and low dose groups after adjusting for baseline BMD. This randomized controlled trial did not demonstrate any efficacy of omega-3 fatty acids on bone loss in adults.The purpose of this study is to investigate whether supplementation with high dose omega-3 fish oil could have an impact on BMD.In a multicentre, double-blind randomized controlled trial (RCT) (ACTRN 12607000415404), 202 Australian participants aged ≥40 with knee osteoarthritis (mean age, 61.0 ± 10.0 years; 49 % female) were randomized to receive either high dose (4.5 g eicosapentaenoic acid and docosahexaenoic acid daily) or low dose (0.45 g/day) omega-3 fish oil for 2 years. BMD was assessed at baseline and 2 years by dual energy X-ray absorptiometry.In subjects with baseline and 2-year assessments, mean standardized BMD at baseline for low or high dose group was 1198 ± 198 and 1157 ± 169 mg/cm(2), respectively, for the lumbar spine and was 1035 ± 165 and 1017 ± 174 mg/cm(2), respectively, for the femoral neck. There were no differences in the 2-year BMD measures between high and low dose groups after adjusting for baseline BMD in the complete case regression analyses (lumbar spine 3.7, 95 % confidence interval (CI) -7.9 to 15.3 mg/cm(2) and femoral neck -5.5, 95 % CI -14.9 to 3.9 mg/cm(2)). The findings did not change with additional adjustments of age, gender, study centre and uses of bone-related drugs during the study period as well as using the intention-to-treat analysis or limiting to older participants (≥55 years at the baseline) (all P ≥ 0.25). Mild adverse events such as headache and gastrointestinal intolerance were common but did not occur more frequently in either group. There were no serious adverse events related to the intervention.A 2-year supplementation with high-dose omega-3 fish oil did not alter bone loss among men and women with knee osteoarthritis. |
Keywords: | Bone mineral density; docosahexaenoic acid; eicosapentaenoic acid; omega-3 fatty acids; randomized controlled trial |
Description: | Published online: 22 December 2015 |
Rights: | © International Osteoporosis Foundation and National Osteoporosis Foundation 2015 |
RMID: | 0030042200 |
DOI: | 10.1007/s00198-015-3438-x |
Grant ID: | http://purl.org/au-research/grants/nhmrc/451900 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.